



## Cancer Steering Committee Annual Scientific Symposium

*Marriott Wardman Park, Washington, DC*

Monday, November 6, 2017      7:30 am – 7:30 pm  
Tuesday, November 7, 2017      7:30 am – 3:00 pm

### Agenda

#### Monday, November 6

7:30 am	<b>Registration and Breakfast</b>
8:00 am	<b>FNIH Welcome</b> —Joe Menetski, Stacey Adam, and Dana Connors
8:15 am	<b>Meeting Introduction</b> —Eric Rubin and Gary Kelloff
8:20 am	<b>Keynote</b> - Dinah Singer – Updates and Current Directions of the Cancer Moonshot
8:50 am	<b>Meeting Overview</b> —Gary Kelloff
9:15 am	<p><b>Session #1 –Precision Medicine in Oncology: Key Scientific Strategies</b> Chair: Gideon Blumenthal (5') – Welcome and Background</p> <ul style="list-style-type: none"> <li>• Barrett Rollins (10') – Project GENIE</li> <li>• Monica Bertagnolli (15') - Advantages of an Open-Access Data Sharing Model</li> <li>• Avrum Spira (15') - Precancer Atlas to Drive Precision Prevention Trials</li> <li>• Elizabeth Mansfield (15') - Insights on Biomarker Development for Precision Medicine</li> </ul> <p>Panel Discussion, Participant Questions and Comments (30')</p> <p>Moderator: Steve Gutman Panelists: Neal Meropol, Malcolm Smith, Sean Khozin, Michael Berger, Elizabeth Mansfield, Monica Bertagnolli</p>
10:45 am	<b>Coffee/Networking</b>
11:15 am	<p><b>Session #2 - Minimal Residual Disease (MRD): The Most Promising Endpoint for Heme-Onc</b> Chair: Nikhil Munshi – Welcome</p> <ul style="list-style-type: none"> <li>• Nikhil Munshi (15') - Multiple Myeloma: Data Needed to Define Context(s) of Use for MRD</li> <li>• Raji Sridhara (10') - ALL: Data Needed to Define Context(s) of Use for MRD</li> <li>• Daniel Auclair (10') - New Technologies to Measure MRD</li> <li>• Kim Jessup (15') - Standardization and Path for Commercialization of a MRD Assay</li> </ul> <p>Panel Discussion, Participant Questions and Comments (40')</p> <p>Moderator: Kim Jessup Panelists: Alessandra DiBacco, Nicole Gormley, Mohamed Hussein, Diko Kazandjian, Greg Reaman, Ilan Kirsch, Jeff Venstrom, Don Berry, Kelly Oliner</p>
12:45 pm	<b>Lunch/Networking</b>

1:45 pm	<p><b>Session #3 - Imaging Science: Progress in Quantitative Imaging—The Importance of Volumetric, Metabolic and Radiomics Measurements</b></p> <p>Chair: Larry Schwartz – Welcome</p> <ul style="list-style-type: none"> <li>• Larry Schwartz (10') - Overview of Session/ Progress and New Strategies for Vol-PACT</li> <li>• Michael Maitland (10') – Oncologist Perspective of Novel Imaging Metric</li> <li>• Mithat Gonen (10') - Modeling Imaging Data</li> <li>• Heiko Schoeder (15') - FDG-PET and Other Tracers to Enhance Quantitative Imaging</li> <li>• Hugo Aerts (15')- Radiomics</li> </ul> <p>Panel Discussion, Participant Questions and Comments (30')</p> <p>Moderator: Dan Sullivan  Panelists: Paula Jacobs, Andrea Perrone, Marc Theoret, Bob Nordstrom, Annette Schmid, Chris Contag</p>
3:15 pm	<p><b>Break/Networking</b></p>
3:45 pm	<p><b>Session #4 - Liquid Biopsy: Cancer Biology— Many Technologies, Many Assays, and the Need for Standards</b></p> <p>Chair: Bob McCormack – Welcome</p> <ul style="list-style-type: none"> <li>• Bob McCormack (10') - Why Are Standards for Liquid Biopsy So Valuable?</li> <li>• Mickey Williams (15') - Workplan for Development of ctDNA Reference Materials</li> <li>• Carl Barrett (10') – Need for Liquid Biopsy Validation</li> <li>• Kapil Dhingra (15') - Exosomes—Liquid Biopsy in Blood and Other Fluids</li> <li>• Howard Scher (10') - AR-V7 in Circulating Tumor Cells in Prostate Cancer</li> <li>• Minetta Liu (10') - Determining Clinical Utility of Assay for BRAF ctDNA</li> <li>• Roy Herbst (10') - Lung-MAP: Opportunities for Longitudinal Follow-Up of Patients with Liquid Biopsy</li> </ul> <p>Panel Discussion, Participant Questions and Comments (40')</p> <p>Moderator: Carl Barrett  Panelists: Ken Cole, Chris Karlovich, Peter Kuhn, Anne-Marie Martin, Reena Philip, Andrew Schade</p>
5:45 pm	<p><b>Break</b></p>
6:00 pm	<p><b>Keynote – TBD</b></p>
6:30 pm	<p><b>Reception</b></p>
7:30 pm	<p><b>Adjourn – Dinner on Your Own</b></p>

**Tuesday, November 7**

<b>7:30 am</b>	<b>Registration and Breakfast</b>
<b>7:50 am</b>	<b>Meeting Overview II—Eric Rubin – Day 2 Introduction</b>
<b>8:00 am</b>	<b>Keynote—Timothy Chan - TBD</b>
<b>8:30 am</b>	<p><b>Session #5 - Immuno-oncology Biomarkers: The Biology of the Immune Response and Need to Understand the Tumor Microenvironment</b></p> <p>Chair: Eric Rubin – Welcome</p> <ul style="list-style-type: none"> <li>• Aviv Regev (or Orit Rosen-Rosenblatt) (15') - Defining Biomarkers of Impact of Chemotherapy on Tumor Immunity by Single-Cell Analysis of the Tumor Environment of (ER+) Metastatic Breast Cancer</li> <li>• Vince Miller (15') - Tumor Mutational Burden as a Predictive Biomarker for Response to Immunotherapy</li> <li>• Angela DeMichele (15') - Evaluation of Pembrolizumab in I-SPY 2</li> <li>• James Gulley (15') - PROSTVAC (Vaccine for Advanced Prostate Cancer)</li> <li>• Alexandre Akoulitchev (15') - Deconvolution of Epigenetic Data with EpiSwitch High Resolution Chromosome Conformation Monitoring for Prognostic Stratifications of Non-Responders to Cancer Immunotherapies</li> <li>• Alexandra Snyder (15') - Immune Profiling and Sequencing</li> </ul> <p>Panel Discussion, Participant Questions and Comments (30')</p> <p>Moderator: Elad Sharon Panelists: Rob Iannone, Theresa LaVallee, David Kaufman, Alessandra Cesano, Magda Thurin</p>
<b>10:30 am</b>	<b>Break/Networking</b>
<b>11:00 am</b>	<p><b>Session #6 – Emerging Technologies: Importance of and Beyond Genomics</b></p> <p>Chair: Greg Friberg (5') – Welcome and Background</p> <ul style="list-style-type: none"> <li>• Henry Rodriguez (15') - Proteogenomics</li> <li>• Josh LaBaer (15') - Immuno-Proteogenomic Predictors for Response to Immunotherapy in Melanoma</li> <li>• Scott Manalis and David Weinstock (15') - Mass and Growth Biomarkers for Precision Medicine</li> <li>• Peter Kuhn (10') - Progress and New Strategies for HD-SCA in Colorectal Cancer</li> </ul> <p>Panel Discussion - (30')</p> <p>Moderator: Jerry Lee Panelists: Julia Beaver, Anahita Bhatena, Steffan Ho, Nas Zahir, Karin Rodland, Lou Staudt</p>
<b>12:30 pm</b>	<b>Lunch/Networking</b>

**Tuesday, November 7**

<b>1:00 pm</b>	<p><b>Session #7 – Prostate Cancer: Emerging Promise and Value of Early Intervention</b></p> <p>Chair: William Dahut (5') – Welcome and Background</p> <ul style="list-style-type: none"> <li>• William Catalona (15') - Translational Genomics Research Leveraging Physician Quality Reporting System Outcomes: A Public-Private Partnership</li> <li>• Michael Brawer (15') - The Prostate Cancer Intervention Versus Treatment (PIVOT) Trial</li> <li>• Ajjai Alva (15') – Protocol in Androgen Insensitive Disease (CATCH)</li> <li>• William Dahut (10') – Perspectives and management of early and late prostate cancer</li> </ul> <p>Panel Discussion, Participant Questions and Comments (30')</p> <p>Moderator: Michael Brawer Panelists: Andrew Hruszkewycz, Stephanie Harmon, Howard Scher, Mike Morris</p>
<b>2:30 pm</b>	<b>Closing Keynote – Gary Gordon – Industry Perspective</b>
<b>3:00 pm</b>	<b>Adjourn</b>

Not Finalized